Comparative Pharmacology
Head-to-head clinical analysis: DURANEST versus LIDOCAINE HYDROCHLORIDE 0 2 AND DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURANEST versus LIDOCAINE HYDROCHLORIDE 0 2 AND DEXTROSE 5 IN PLASTIC CONTAINER.
DURANEST vs LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.
Lidocaine is a sodium channel blocker that stabilizes neuronal membranes by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby producing local anesthesia. Dextrose 5% provides caloric support.
2-10 mL of a 1-2% solution, subarachnoid injection, single dose only.
Intravenous administration: Initial dose of 1-1.5 mg/kg (up to 300 mg total) given at a rate not exceeding 50 mg/min. Followed by continuous infusion at 1-4 mg/min (20-50 mcg/kg/min) for arrhythmia management.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours (range 3-6 hours). Clinical context: Prolonged in severe hepatic impairment but not significantly in renal impairment.
Terminal elimination half-life: 1.5–2 hours (prolonged to 2–3 hours in hepatic impairment; unchanged in renal impairment).
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug. Biliary/fecal elimination is minimal.
Renal excretion of unchanged drug and metabolites: 10% unchanged, 90% as metabolites (primarily 4-hydroxy-2,6-xylidine and glycylxylidide). Less than 1% biliary/fecal.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)